Progenics Pharmaceuticals (NASDAQ: PGNX) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Progenics Pharmaceuticals to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, institutional ownership, dividends and valuation.
Earnings and Valuation
This table compares Progenics Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Progenics Pharmaceuticals||$69.43 million||$10.80 million||-6.84|
|Progenics Pharmaceuticals Competitors||$288.06 million||$35.21 million||146.76|
This table compares Progenics Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Progenics Pharmaceuticals Competitors||-5,605.16%||-475.23%||-39.70%|
This is a summary of current ratings for Progenics Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Progenics Pharmaceuticals Competitors||795||3155||11435||229||2.71|
Progenics Pharmaceuticals presently has a consensus target price of $13.20, suggesting a potential upside of 144.44%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.11%. Given Progenics Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Progenics Pharmaceuticals is more favorable than its competitors.
Insider & Institutional Ownership
89.2% of Progenics Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.6% of Progenics Pharmaceuticals shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Progenics Pharmaceuticals has a beta of 3.5, suggesting that its share price is 250% more volatile than the S&P 500. Comparatively, Progenics Pharmaceuticals’ competitors have a beta of 7.22, suggesting that their average share price is 622% more volatile than the S&P 500.
Progenics Pharmaceuticals beats its competitors on 8 of the 12 factors compared.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.